Companies
/
A-Alpha Bio
Healthtech
A-Alpha Bio is a Seattle biotechnology company that combines synthetic biology and machine learning to measure and predict how proteins bind to one another.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
A-Alpha Bio was founded in 2017 as a spinout of the Institute for Protein Design at the University of Washington, home to some of the foundational research behind modern computational protein design. The company's core insight is that while tools like AlphaFold made it possible to predict a protein's three-dimensional structure, predicting how strongly and specifically two proteins will bind to each other, a property central to nearly every disease and therapeutic, remained a bottleneck. A-Alpha Bio built two complementary platforms to address this: AlphaSeq, an experimental library-on-library system that can quantitatively measure millions of protein-protein binding interactions simultaneously, and AlphaBind, a machine learning model trained on that experimental data to predict binding strength directly from protein sequence. The company has used these platforms both for its own therapeutic pipeline, which focuses on molecular glues and cytokine-based biologics such as immunocytokines, and in partnership with pharmaceutical companies seeking to discover and optimize antibodies and other biologics. A-Alpha Bio has raised more than $51 million to date and has processed over a billion experimentally measured protein-protein interactions using AlphaSeq. In 2024 the company worked with NVIDIA's BioNeMo framework on AWS to scale its binding-prediction throughput roughly tenfold, and in 2026 it announced an industry data consortium, with founding members including GSK, Boltz, Cradle, and Dyno Therapeutics, aimed at generating large-scale standardized antibody-antigen datasets to help address the shortage of high-quality experimental data needed to train protein AI models.
Sources:
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
